Dr Noa Sher
Every day, together with the world’s leading scientists, clinicians and patient groups we are translating our mitochondrial science into meaningful therapies for mitochondrial diseases – from ultra-rare to more common ones.
Dr Noa Sher is a Chief Scientist at the Minovia Therapeutics LTD, Haifa, Israel.
Minovia Therapeutics has developed a unique treatment for mitochondrial diseases. Mitochondrial augmentation technology (MAT) is an autologous cell therapy developed to treat patients with primary mitochondrial diseases. In MAT patient-derived hematopoietic stem and progenitor cells are enriched ex-vivo with healthy donor mitochondria and reinfused to the bloodstream. To date, Dr. Sher’s team has treated 12 patients with different mitochondrial DNA syndromes and preliminary data indicate safety and initial signs of efficacy in multiple organs, including muscle, brain, liver and kidney. Currently, Dr Sher’s team is developing syngeneic generic healthy mitochondria produced from the human placenta.
Dr Sher is supervising DC10 and industry-supervising DC2 and DC8.
- Jacoby E. et al. (2021), Mitochondrial augmentation of CD34+ cells from healthy donors and patients with mitochondrial DNA disorders confers functional benefit. npj Regen Med 6, 58. Sher N., Napso T. and Shabtay-Orbach A. are co-authors. DOI
In previous roles, Dr. Sher headed a research team responsible for preclinical development of several clinical stage allogeneic cell therapy products and founded and headed a bioinformatics and sequencing service unit at the University of Haifa. Dr. Sher is a molecular and cellular biologist by training who performed her postdoctoral studies at the Whitehead Institute, MIT, Cambridge, MA and at the Technion Institute of Technology in Israel and earned her PhD in Biochemistry at the Hebrew University. She currently serves as the Chief Scientific Officer at Minovia Therapeutics, a clinical stage company developing a mitochondrial cell therapy approach to treat mitochondrial and hematopoietic diseases.
